Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1945]
News [3579]
Articles [92]
Editorials [5]
Conferences [156]
elearning [19]
ASCO 2025: Experimental Drug Development Centre announces the presentation of updated data from the phase 1 study of antibody-drug conjugate EBC-129 at the 2025 Annual Meeting of the American Society of Clinical Oncology (ASCO)
ASCO 2025: Experimental Drug Development Centre announces the presentation of updated data from the phase 1 study...
Bioactive soluble recombinant mouse LIGHT protein promotes effective tumour immune cell infiltration delaying tumour growth
Bioactive soluble recombinant mouse LIGHT protein promotes effective tumour immune cell infiltration delaying...
ASCO 2025: Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast cancers
ASCO 2025: Trastuzumab deruxtecan plus pertuzumab may delay cancer growth for some HER2-positive advanced breast...
ASCO 2025: Ramucirumab and pembrolizumab combo does not improve OS for previously treated advanced NSCLC
ASCO 2025: Ramucirumab and pembrolizumab combo does not improve OS for previously treated advanced NSCLC
ASCO 2025: Nivolumab plus chemo before surgery improves lung cancer survival
ASCO 2025: Nivolumab plus chemo before surgery improves lung cancer survival
ASCO 2025: Avelumab cetuximab combo improves PFS for for cutaneous squamous cell carcinoma
ASCO 2025: Avelumab cetuximab combo improves PFS for for cutaneous squamous cell carcinoma
ASCO 2025: Adding nivolumab to chemoradiotherapy after surgery can decrease chance of recurrence in head and neck cancer
ASCO 2025: Adding nivolumab to chemoradiotherapy after surgery can decrease chance of recurrence in head and neck...
ASCO 2025: Dual-target CAR T-cell therapy slows growth of aggressive brain cancer
ASCO 2025: Dual-target CAR T-cell therapy slows growth of aggressive brain cancer
ASCO 2025: Atezolizumab chemo combo leads to improved survival in deficient mismatch repair colon cancer
ASCO 2025: Atezolizumab chemo combo leads to improved survival in deficient mismatch repair colon cancer
ASCO 2025: Perioperative treatment with durvalumab and FLOT chemo can reduce risk of recurrence for some gastric cancers
ASCO 2025: Perioperative treatment with durvalumab and FLOT chemo can reduce risk of recurrence for some gastric...

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation